ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer's Disease
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Mayo Clinic
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Safety and Tolerability
研究概览
简要总结
This study is being done to evaluate the safety and feasibility of using Dasatinib and Quercetin together in subjects with Mild Cognitive Impairment (MCI) or Alzheimer's disease.
详细描述
The underlying processes driving chronic neurodegeneration in Alzheimer's disease (AD) and related neurodegenerative disorders are largely unknown. Aging is the major risk factor for AD. Moreover, individuals with AD suffer from significantly more co-morbid conditions than demographically matched older adults. This study is an open-label pilot study of intermittent administration of the senolytic drug regimen Dasatinib (D) + Quercetin (Q) in symptomatic adults over 55 with clinical diagnosis of probable Alzheimer's Disease and Alzheimer's biomarker positivity by tau-PET.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women of age 55 years and older at the time of enrollment
- •Clinical diagnosis of symptomatic probable AD (MMSE 26 to 15 or Short Test of Mental Status 31 to 15 inclusive and/or Clinical Dementia Rating Scale/CDR = 0.5 to 2, inclusive)
- •Not on cholinesterase inhibitors or memantine; or if on cholinesterase inhibitors and/or memantine, on a stable dose for at least three months
- •Body Mass Index (BMI) within range of 19 - 50 kg/ m2
- •Participants must be accompanied by a LAR designated to sign informed consent and to provide study partner reported outcomes at all visits
- •Participants must have no plans to travel over the ~3 months between Visits 3 and 14 that interfere with study visits
- •Tau positivity by brain PET imaging
- •Adequate blood counts i.e. platelets > 50,000 per microliter; HB > 9/dL, and ANC > 1000 per microliter
- •Availability and consent from a LAR.
排除标准
- •Unwilling or unable to give informed consent
- •QTc > 450 msec on baseline ECG
- •MRI contraindications
- •Presence of uncontrolled psychiatric disorder (as per clinical judgment)
- •Presence of uncontrolled systemic lupus erythematosus (as per clinical judgment)
- •Substance or alcohol abuse (current alcohol use > 3 alcoholic beverage/day or > 21 per week and as per clinical judgment)
- •Hearing, vision, or motor deficits despite corrective devices (as per clinical judgment)
- •Myocardial infarction, angina, stroke, or transient ischemic attack in the past 6 months
- •Chronic heart failure (as per clinical judgment)
- •Neurologic, musculoskeletal, or other condition that limits subject's ability to complete study physical assessments (as per clinical judgment)
- •Positive SARS-CoV-2 test within 30 days prior to enrollment
- •AST/ALT > 2.5x upper limit normal
- •Presence of significant liver disease with total bilirubin > 2X upper limit or as per clinical judgment
- •Inability to tolerate oral medication (as per clinical judgment)
- •Abnormality in any of the screening laboratory studies (see section 6.21.2) or as per clinical judgment
- •Malabsorption (as per clinical judgment)
- •Known human immunodeficiency virus infection (as per clinical judgment)
- •Known active hepatitis B or C infection
- •Invasive fungal or viral infection (as per clinical judgment)
- •Known hypersensitivity or allergy to D or Q
- •Uncontrolled pleural/pericardial effusions or ascites (as per clinical judgment)
- •New/active invasive cancer except non-melanoma skin cancers
- •Inability to tolerate oral medications (as per clinical judgment)
- •Currently taking AND unable to safely hold any of the medications listed in Appendix 1 during the days IP is administered and for 36 hours after IP administration.
- •Uncontrolled diabetes (defined as HbA1c > 7% or as per clinical judgment).
- •Gastric bypass/reduction
- •Crohn's disease
- •Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase or ESR) (as per clinical judgment)
- •eGFR < 10 ml/ min/ 1.73 m2
- •Creatinine clearance < 60 mL/min/1.73 m2
- •Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.)
- •On antiplatelet agents (e.g., full dose Aspirin, Clopidogrel etc.). Baby aspirin (81 mg), if absolutely necessary from cardiac perspective, will be allowed
- •Presence of any condition that the Investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial
- •Involvement of special vulnerable populations: We will not involve special vulnerable populations, such as fetuses, neonates, pregnant women, children, prisoners, institutionalized individuals, or others who may be considered vulnerable populations except for patients with dementia. Therefore, availability and consent from a LAR is an inclusion criterion.
研究组 & 干预措施
Dasatinib plus Quercetin Treatment Goup
Subjects with MCI or Alzheimer's disease will take Dasatinib and Quercetin by mouth at the same times for 2 days out of every 15 days for 6 cycles lasting for a total of 77 days (12 concurrent doses of each agent).
干预措施: Quercetin (Drug)
Dasatinib plus Quercetin Treatment Goup
Subjects with MCI or Alzheimer's disease will take Dasatinib and Quercetin by mouth at the same times for 2 days out of every 15 days for 6 cycles lasting for a total of 77 days (12 concurrent doses of each agent).
干预措施: Dasatinib (Drug)
结局指标
主要结局
Safety and Tolerability
时间窗: 11 weeks
Safety evaluations will be conducted including assessment for adverse events, compliance to the study drug regimen, physical examinations or assessments, vital signs, and laboratory assessments.
次要结局
未报告次要终点
研究者
Vijay K. Ramanan
Assistant Professor of Neurology
Mayo Clinic